Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs)

Promise, perils and cautious optimism

(2022) Morgan M. Philbin et al.   Current Opinion in HIV and AIDS

High willingness to use injectable antiretroviral therapy among women who have been lost to follow‐up from HIV programmes: A nested cross‐sectional study

(2022) Eva Laker Agnes Odongpiny et al.   HIV MEDICINE

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

(2022) Sinead Delany-Moretlwe et al.   LANCET

Drug resistance and use of long-acting ART

(2022) Juliana da Silva et al.   Lancet HIV

Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study

(2021) Ben Parker et al.   PLoS One

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis

(2021) Andrew N Phillips et al.   Lancet Global Health

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

(2021) Raphael J. Landovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of long-acting therapies on the global HIV epidemic

(2021) Nomathemba C. Chandiwana et al.   AIDS

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

(2021) Hans Jaeger et al.   Lancet HIV

Cabotegravir Plus Rilpivirine: First Approval

(2020) A. Markham   DRUGS

“A dream come true”: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania

(2020) Deanna Kerrigan et al.   PLoS One

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

(2020) Raphael J Landovitz et al.   Lancet HIV

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)

(2019) Leah M. Johnson et al.   Pharmaceutics

Long-acting implants to treat and prevent HIV infection

(2019) Ethel D. Weld et al.   Current Opinion in HIV and AIDS

Current and future priorities for the development of optimal HIV drugs

(2018) Marco Vitoria et al.   Current Opinion in HIV and AIDS

The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy

(2015) Eric L. Ross et al.   CLINICAL INFECTIOUS DISEASES

Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection

(2015) Rochelle P. Walensky et al.   JOURNAL OF INFECTIOUS DISEASES

Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men

(2012) P. L. Anderson et al.   Science Translational Medicine